Spyre Therapeutics (SYRE) Director McKenna Receives Option Award

What Happened Mark C. McKenna, a director of Spyre Therapeutics, was granted a derivative award representing the right to purchase 8,026 shares of the company's common stock. The reported acquisition price is $0.00, so there is no immediate cash value recorded in the filing. This is an award of option rights (transaction code A), not a market purchase or sale.

Key Details

• Transaction date: 2026-05-27; Form 4 filed: 2026-05-29 (timely filing).
• Instrument: Option/award to acquire 8,026 shares (derivative); reported price $0.00; reported value $0.
• Vesting: Becomes fully exercisable on the earlier of May 27, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, subject to McKenna’s continuous service through the applicable vesting date (per footnote).
• Shares owned after transaction: Not specified in the filing.
• Transaction type: Award/grant (A) — not a purchase or sale; no immediate sale or exercise reported.

Context This grant gives McKenna the right to buy shares in the future if vesting conditions are met; it is common compensation for directors and does not involve an immediate cash exchange. Because vesting depends on continued service and a future date/event, the award may serve as a retention incentive rather than an immediate market signal.